AU2001216030A1 - A method for generating genetically altered antigens - Google Patents

A method for generating genetically altered antigens

Info

Publication number
AU2001216030A1
AU2001216030A1 AU2001216030A AU1603001A AU2001216030A1 AU 2001216030 A1 AU2001216030 A1 AU 2001216030A1 AU 2001216030 A AU2001216030 A AU 2001216030A AU 1603001 A AU1603001 A AU 1603001A AU 2001216030 A1 AU2001216030 A1 AU 2001216030A1
Authority
AU
Australia
Prior art keywords
useful
genes
methods
cells
generating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001216030A
Inventor
Luigi Grasso
Nicholas C. Nicolaides
Philip M. Sass
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morphotek Inc
Original Assignee
Morphotek Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphotek Inc filed Critical Morphotek Inc
Publication of AU2001216030A1 publication Critical patent/AU2001216030A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

Dominant negative alleles of human mismatch repair genes can be used to generate hypermutable cells and organisms. By introducing these genes into cells and transgenic animals, new cell lines animal varieties with novel and useful properties can be prepared more efficiently than by relying on the natural rate of mutation. These methods are useful for generating genetic diversity within genes encoding for therapeutic antigens to produce altered polypeptides with enhanced antigenic and immunogenic activity. Moreover, these methods are useful for generating effective vaccines.
AU2001216030A 2000-11-14 2000-11-14 A method for generating genetically altered antigens Abandoned AU2001216030A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/031135 WO2002040499A1 (en) 2000-11-14 2000-11-14 A method for generating genetically altered antigens

Publications (1)

Publication Number Publication Date
AU2001216030A1 true AU2001216030A1 (en) 2002-05-27

Family

ID=21741992

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001216030A Abandoned AU2001216030A1 (en) 2000-11-14 2000-11-14 A method for generating genetically altered antigens

Country Status (8)

Country Link
EP (1) EP1363930B1 (en)
JP (1) JP2005509399A (en)
AT (1) ATE336505T1 (en)
AU (1) AU2001216030A1 (en)
CA (1) CA2429134C (en)
DE (1) DE60030172T2 (en)
DK (1) DK1363930T3 (en)
WO (1) WO2002040499A1 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917017A (en) * 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
JP3846808B2 (en) * 1994-06-17 2006-11-15 インステイテユート・ボール・デイールホウデリイ・エン・デイールゲゾンドハイド Nucleotide sequences of pestivirus strains, polypeptides encoded by these sequences, and their use for diagnosis and prevention of pestivirus infections
AU3241095A (en) * 1994-07-29 1996-03-04 Chiron Corporation Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same
US5612030A (en) * 1995-01-17 1997-03-18 University Of Kentucky Research Foundation Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US5843757A (en) * 1995-08-24 1998-12-01 The Johns Hopkins University Human JTV1 gene overlaps PMS2 gene
AU752191B2 (en) * 1997-07-31 2002-09-12 Hawaii Biotech, Inc. Recombinant dimeric envelope vaccine against flaviviral infection
US6146894A (en) * 1998-04-14 2000-11-14 The Johns Hopkins University Method for generating hypermutable organisms

Also Published As

Publication number Publication date
CA2429134A1 (en) 2002-05-23
EP1363930B1 (en) 2006-08-16
WO2002040499A1 (en) 2002-05-23
CA2429134C (en) 2011-03-15
DE60030172T2 (en) 2007-07-05
EP1363930A1 (en) 2003-11-26
EP1363930A4 (en) 2004-04-14
JP2005509399A (en) 2005-04-14
DK1363930T3 (en) 2006-09-04
DE60030172D1 (en) 2006-09-28
ATE336505T1 (en) 2006-09-15

Similar Documents

Publication Publication Date Title
CA2240609A1 (en) A method for generating hypermutable organisms
WO2004024871A3 (en) Antibodies and methods for generating genetically altered antibodies with high affinity
TWI255853B (en) Method for modifying chromosomes
SG41951A1 (en) Isolation selection and propagation of animal stem cells genetically modified animals and animals cells and constructs for their production
AU2003210405A1 (en) Inbred embryonic stem-cell derived mice
CA2230759A1 (en) Chimeric animal and method for producing the same
IL166771A0 (en) Method for producing ketocarotinoids in genetically modified organisms
EP1196426A4 (en) Cytoplasmic transfer to de-differentiate recipient cells
HK1083635A1 (en) Animal protein free media for cultivation of cells
MX9709745A (en) Methods and constructs for producing male sterile plants.
AU2002311989A8 (en) Methods and materials for the production of organic products in cells of $i(candida) species
NZ514025A (en) Compositions and methods for the modification of gene transcription
WO2001088192A3 (en) A method for generating hypermutable organisms
HUP0002649A2 (en) Induction of male sterility in plants by expression of high levels of avidin
EP1534066A4 (en) Alpha(1,3)-galactosyltransferase null cells, methods of selecting and alpha(1,3)-galactosyltransferase null swine produced therefrom
DK1159415T3 (en) Genetic modification of somatic cells and their use
ATE455179T1 (en) HUMAN CHROMOSOME FRAGMENT AND A VECTOR CONTAINING IT
ATE501635T1 (en) MISMATCH REPAIR CHEMICAL INHIBITORS
AU2001216030A1 (en) A method for generating genetically altered antigens
TR200002974T2 (en) Live vaccine against brucellosis
CN109722436A (en) The carrier of the seamless editor of genome based on CRISPR-Cas9 and application
CN101836553A (en) Artificially acclimated antrodia cinnamomea reduction and simulation natural environment
EP1551988A4 (en) Methods for generating enhanced antibody-producing cell lines with improved growth characteristics
AU2003246369A1 (en) Vaccination with immuno-isolated cells producing an immunomodulator
WO2000004918A3 (en) Agents for the immunotherapy of tumoral diseases